Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $62
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Vamil Divan has maintained a 'Buy' rating on ANI Pharmaceuticals (NASDAQ:ANIP) and raised the price target from $59 to $62.
July 27, 2023 | 2:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ANI Pharmaceuticals' price target has been raised from $59 to $62 by Guggenheim, maintaining a 'Buy' rating.
The raised price target and maintained 'Buy' rating by Guggenheim indicates a positive outlook for ANI Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100